What is the appropriate evaluation and management for a 25‑year‑old woman with a copper intrauterine device who recently discontinued sertraline and is now experiencing frequent spotting while the IUD remains in place?

Evaluation and Management of Spotting in a Copper IUD User After Sertraline Discontinuation

First, reassure the patient that spotting with a copper IUD is generally not harmful, then systematically evaluate for underlying gynecological problems—particularly IUD displacement, pregnancy, STIs, and new uterine pathology—before considering symptomatic treatment with NSAIDs if no pathology is found. 1

Initial Assessment Priority

The timing of sertraline discontinuation is likely coincidental rather than causative. While SSRIs like sertraline can affect bleeding through platelet function 2, the copper IUD itself is the more probable culprit for spotting patterns.

Key Clinical Evaluation Steps

If clinically indicated, evaluate for:

• IUD displacement - Check for visible strings; consider pelvic exam to confirm proper positioning 1
• Pregnancy - Rule out both intrauterine and ectopic pregnancy 3
• Sexually transmitted infections 1
• New pathologic uterine conditions - polyps, fibroids, or other structural abnormalities 1, 3
• Medication interactions or thyroid disorders 1

This evaluation is especially important if the patient has been using the copper IUD for several months or longer and has developed new-onset bleeding patterns 3.

Management Algorithm

If No Underlying Pathology Found:

1. Reassurance and Expectant Management

• Spotting and light bleeding are common with copper IUDs, particularly in the first 3-6 months, but can occur throughout use 1, 3
• These irregularities are generally not harmful and often decrease with continued use 3
• Advise the patient they may contact you at any time to discuss bleeding concerns 1

2. If Patient Desires Treatment:

• NSAIDs for 5-7 days during bleeding episodes 1
  • Multiple studies demonstrate NSAIDs significantly reduce menstrual blood loss in copper IUD users 3, 4
  • Options include ibuprofen, mefenamic acid, or other NSAIDs 3

3. If Bleeding Persists and Is Unacceptable:

• Counsel on alternative contraceptive methods
• Offer IUD removal and initiation of another method if desired 1, 3

Important Clinical Pitfalls

Avoid attributing the spotting solely to sertraline discontinuation. While sertraline affects platelet function and bleeding risk 2, copper IUDs themselves are well-established causes of bleeding irregularities 3, 4. The discontinuation of sertraline is unlikely to be the primary driver of new spotting patterns.

Do not overlook structural causes. New-onset bleeding in an established IUD user warrants evaluation for displacement, infection, or uterine pathology 1, 3. A shorter uterine cavity length is associated with increased menorrhagia risk 5, and IUD displacement correlates with pelvic cramping 5.

Consider the copper surface area effect. Higher copper content IUDs (>250 mm²) are associated with increased bleeding 6, 7, though this is less relevant for management than for initial device selection.

Sertraline Discontinuation Considerations

While evaluating the bleeding, monitor for sertraline discontinuation symptoms including dysphoric mood, irritability, dizziness, and sensory disturbances 2. These symptoms are generally self-limiting but should be managed separately from the IUD-related bleeding 2.